These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12127792)

  • 1. Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV.
    Enose Y; Ui M; Miyake A; Suzuki H; Uesaka H; Kuwata T; Kunisawa J; Kiyono H; Takahashi H; Miura T; Hayami M
    Virology; 2002 Jul; 298(2):306-16. PubMed ID: 12127792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination.
    Enose Y; Kita M; Yamamoto T; Suzuki H; Miyake A; Horiuchi R; Ibuki K; Kaneyasu K; Kuwata T; Takahashi E; Sakai K; Shinohara K; Miura T; Hayami M
    Arch Virol; 2004 Sep; 149(9):1705-20. PubMed ID: 15593414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
    Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
    J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective efficacy of nonpathogenic nef-deleted SHIV vaccination combined with recombinant IFN-gamma administration against a pathogenic SHIV challenge in rhesus monkeys.
    Kaneyasu K; Kita M; Ohkura S; Yamamoto T; Ibuki K; Enose Y; Sato A; Kodama M; Miura T; Hayami M
    Microbiol Immunol; 2005; 49(12):1083-94. PubMed ID: 16365534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS.
    Joag SV; Liu ZQ; Stephens EB; Smith MS; Kumar A; Li Z; Wang C; Sheffer D; Jia F; Foresman L; Adany I; Lifson J; McClure HM; Narayan O
    J Virol; 1998 Nov; 72(11):9069-78. PubMed ID: 9765452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of simian and human immunodeficiency chimeric viruses re-isolated from vaccinated macaque monkeys after challenge infection.
    Kwofie TB; Miura T; Ibuki K; Enose Y; Suzuki H; Ui M; Kuwata T; Hayami M
    Arch Virol; 2002 Jun; 147(6):1091-104. PubMed ID: 12111421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
    Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
    AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Live-attenuated lentivirus immunization modulates innate immunity and inflammation while protecting rhesus macaques from vaginal simian immunodeficiency virus challenge.
    Genescà M; Ma ZM; Wang Y; Assaf B; Qureshi H; Fritts L; Huang Y; McChesney MB; Miller CJ
    J Virol; 2012 Sep; 86(17):9188-200. PubMed ID: 22696662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA vaccine protection against challenge with simian/human immunodeficiency virus 89.6 in rhesus macaques.
    Habel A; Chanel C; Le Grand R; Martinon F; Couillin L; Moog C; Doms R; Gauduin MC; Hurtrel B; Guillet JG; Aubertin AM; Girard M
    Dev Biol (Basel); 2000; 104():101-5. PubMed ID: 11713807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs.
    Ui M; Kuwata T; Igarashi T; Ibuki K; Miyazaki Y; Kozyrev IL; Enose Y; Shimada T; Uesaka H; Yamamoto H; Miura T; Hayami M
    Virology; 1999 Dec; 265(2):252-63. PubMed ID: 10600597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of SHIV for testing HIV-1 vaccine candidates in macaques.
    Lu Y; Salvato MS; Pauza CD; Li J; Sodroski J; Manson K; Wyand M; Letvin N; Jenkins S; Touzjian N; Chutkowski C; Kushner N; LeFaile M; Payne LG; Roberts B
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jun; 12(2):99-106. PubMed ID: 8680896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infectivity and immunogenicity of SIVmac/HIV-1 chimeric viruses (SHIVs) with deletions in two or three genes (vpr, nef and vpx).
    Igarashi T; Kuwata T; Yamamoto H; Moriyama H; Ui M; Miyazaki Y; Hayami M
    Microbiol Immunol; 1998; 42(1):71-4. PubMed ID: 9525784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection.
    Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y
    AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239.
    Miller CJ; McChesney MB; Lü X; Dailey PJ; Chutkowski C; Lu D; Brosio P; Roberts B; Lu Y
    J Virol; 1997 Mar; 71(3):1911-21. PubMed ID: 9032322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses.
    Abel K; Compton L; Rourke T; Montefiori D; Lu D; Rothaeusler K; Fritts L; Bost K; Miller CJ
    J Virol; 2003 Mar; 77(5):3099-118. PubMed ID: 12584336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates.
    Bertley FM; Kozlowski PA; Wang SW; Chappelle J; Patel J; Sonuyi O; Mazzara G; Montefiori D; Carville A; Mansfield KG; Aldovini A
    J Immunol; 2004 Mar; 172(6):3745-57. PubMed ID: 15004179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
    Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC
    J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts.
    Putkonen P; Quesada-Rolander M; Leandersson AC; Schwartz S; Thorstensson R; Okuda K; Wahren B; Hinkula J
    Virology; 1998 Oct; 250(2):293-301. PubMed ID: 9792840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.
    Bogers WM; Davis D; Baak I; Kan E; Hofman S; Sun Y; Mortier D; Lian Y; Oostermeijer H; Fagrouch Z; Dubbes R; van der Maas M; Mooij P; Koopman G; Verschoor E; Langedijk JP; Zhao J; Brocca-Cofano E; Robert-Guroff M; Srivastava I; Barnett S; Heeney JL
    Virology; 2008 Dec; 382(2):217-25. PubMed ID: 18947849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.